Updated results from a large clinical trial confirm that, for some patients with bladder cancer that can be removed with surgery, receiving immunotherapy immediately afterwards is an effective treatment. Read More ›

Cabozantinib-Atezolizumab Combination Shows Activity in Difficult-to-Treat Prostate Cancer
San Francisco, CA—Combining cabozantinib (Cabometyx) with atezolizumab (Tecentriq) induced responses in 32% of patients with metastatic castration-resistant prostate cancer (CRPC) who had soft-tissue progression after previous novel hormonal therapy. Read More ›

The FDA has granted priority review to Merck’s supplemental Biologics License Application for the anti-PD–1 agent pembrolizumab as monotherapy for certain patients with high-risk, non-muscle invasive bladder cancer who are ineligible for or have elected not to undergo cystectomy. Read More ›

Chicago, IL—With 475 cell and gene therapy companies in North America representing a business enterprise with approximately $20 billion, new immunotherapies are moving rapidly from the laboratory to the clinic. As chimeric antigen receptor (CAR) T-cell therapy makes its way from the academic to the community setting, however, appropriate resources and infrastructure are required to ensure the safe and effective management of patients. Read More ›

First Positive Showing for Mesothelin-Directed CAR T-Cell Therapy in Solid Tumors
Atlanta, GA—Chimeric antigen receptor (CAR) T-cell therapy has had dramatic results in hematologic malignancies, but so far, getting CAR T-cells to work in solid tumors has proved elusive. That may be about to change if promising results from a phase 1 clinical trial are confirmed by further studies. The results of this pivotal study were presented at the 2019 American Association for Cancer Research (AACR) annual meeting. Read More ›

Checkpoint Inhibition Consolidation Therapy Promising in High-Risk Hematologic Malignancies
San Diego, CA—Patients with relapsed, refractory, or high-risk hematologic malignancies obtained durable benefits with the combined checkpoint inhibition with nivolumab (Opdivo) and ipilimumab (Yervoy) as consolidation therapy after stem-cell transplant, according to results of a small prospective study presented at ASH 2018. Read More ›

Explosive Development of BCMA CAR T-Cell Therapies for Multiple Myeloma
San Diego, CA—A dizzying array of new chimeric antigen receptor (CAR) T-cell therapies targeting the B-cell maturation antigen (BCMA) designed specifically for the treatment of multiple myeloma was presented at ASH 2018. BCMA-targeted CAR T-cell therapies are designed to improve T-cell persistence, depth of response, and tolerability. Response rates reported at ASH 2018 range from 70% to 100%, depending on the patient population and the use of previous regimens. Read More ›

Although chimeric antigen receptor (CAR) T-cell therapy has achieved remarkable long-­lasting remissions in B-cell malignancies, in approximately 60%, the initial response wanes over time because of “immune exhaustion.” Read More ›

Page 1 of 3

Subscribe Today!

To sign up for our newsletter or print publications, please enter your contact information below.

I'd like to receive: